Imipenem/cilastatin
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Methicillin-resistant Staphylococcus Aureus
Conditions
Methicillin-resistant Staphylococcus Aureus, Pneumonia, Ventilator-Associated
Trial Timeline
Jun 1, 2011 → —
NCT ID
NCT01356472About Imipenem/cilastatin
Imipenem/cilastatin is a approved stage product being developed by Pfizer for Methicillin-resistant Staphylococcus Aureus. The current trial status is unknown. This product is registered under clinical trial identifier NCT01356472. Target conditions include Methicillin-resistant Staphylococcus Aureus, Pneumonia, Ventilator-Associated.
What happened to similar drugs?
0 of 1 similar drugs in Methicillin-resistant Staphylococcus Aureus were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01356472 | Approved | UNKNOWN |
Competing Products
2 competing products in Methicillin-resistant Staphylococcus Aureus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin | AbbVie | Phase 3 | 40 |
| Linezolid + Vancomycin | Pfizer | Pre-clinical | 26 |